Binfeng Lu

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6138953/binfeng-lu-publications-by-year.pdf
Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

46 papers	8,146 citations	20 h-index	49 g-index
49 ext. papers	9,353 ext. citations	7.7 avg, IF	4.67 L-index

#	Paper	IF	Citations
46	Autologous Cytokine-Induced Killer Cell Immunotherapy Enhances Chemotherapy Efficacy against Multidrug-Resistant Tuberculosis.. *Journal of Immunology Research*, **2022**, 2022, 2943113	4.5	
45	The Half-Life-Extended IL21 can Be Combined With Multiple Checkpoint Inhibitors for Tumor Immunotherapy. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 779865	5.7	1
44	A novel immunochemotherapy based on targeting of cyclooxygenase and induction of immunogenic cell death. *Biomaterials*, **2021**, 270, 120708	15.6	5
43	Development and application of sensitive, specific, and rapid CRISPR-Cas13-based diagnosis. *Journal of Medical Virology*, **2021**, 93, 4198-4204	19.7	10
42	Eomes Impedes Durable Response to Tumor Immunotherapy by Inhibiting Stemness, Tissue Residency, and Promoting the Dysfunctional State of Intratumoral CD8 T Cells. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 640224	5.7	7
41	LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance. *Science Advances*, **2021**, 7,	14.3	9
40	Farnesylthiosalicylic acid-derivatized PEI-based nanocomplex for improved tumor vaccination. *Molecular Therapy - Nucleic Acids*, **2021**, 26, 594-602	10.7	2
39	Targeting metabotropic glutamate receptor 4 for cancer immunotherapy. *Science Advances*, **2021**, 7, eabj4226	14.3	0
38	Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment. *OncoImmunology*, **2020**, 9, 1708064	7.2	11
37	IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses. *Frontiers in Immunology*, **2020**, 11, 634	8.4	5
36	CD8 T cells located in tertiary lymphoid structures are associated with improved prognosis in patients with gastric cancer. *Oncology Letters*, **2020**, 20, 2655-2664	2.6	3
35	Differential Requirement of Beclin 1 for Regulating the Balance of Naïve and Activated CD4 T Cells. *Frontiers in Cell and Developmental Biology*, **2020**, 8, 834	5.7	1
34	Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy. *Acta Biomaterialia*, **2020**, 106, 289-300	10.8	17
33	Immune suppressed tumor microenvironment by exosomes derived from gastric cancer cells via modulating immune functions. *Scientific Reports*, **2020**, 10, 14749	4.9	21
32	Tumor-Derived IL33 Promotes Tissue-Resident CD8 T Cells and Is Required for Checkpoint Blockade Tumor Immunotherapy. *Cancer Immunology Research*, **2020**, 8, 1381-1392	12.5	9
31	IL-36Promotes CD8 T Cell Activation and Antitumor Immune Responses by Activating mTORC1. *Frontiers in Immunology*, **2019**, 10, 1803	8.4	12
30	Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy. *Acta Biomaterialia*, **2019**, 90, 300-313	10.8	32

29	B7-H3 promotes aerobic glycolysis and chemoresistance in colorectal cancer cells by regulating HK2. *Cell Death and Disease*, **2019**, 10, 308	9.8	69
28	Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. *Oncogene*, **2019**, 38, 390-405	9.2	68
27	Targeted codelivery of doxorubicin and IL-36γ expression plasmid for an optimal chemo-gene combination therapy against cancer lung metastasis. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2019**, 15, 129-141	6	20
26	Novel Effector Phenotype of Tim-3 Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. *Clinical Cancer Research*, **2018**, 24, 4529-4538	12.9	52
25	Lower expression level of IL-33 is associated with poor prognosis of pulmonary adenocarcinoma. *PLoS ONE*, **2018**, 13, e0193428	3.7	20
24	Improved Cancer Immunochemotherapy via Optimal Co-delivery of Chemotherapeutic and Immunomodulatory Agents. *Molecular Pharmaceutics*, **2018**, 15, 5162-5173	5.6	17
23	ATF4 Regulates CD4 T Cell Immune Responses through Metabolic Reprogramming. *Cell Reports*, **2018**, 23, 1754-1766	10.6	38
22	ST2/IL-33-Dependent Microglial Response Limits Acute Ischemic Brain Injury. *Journal of Neuroscience*, **2017**, 37, 4692-4704	6.6	116
21	Interleukin-33 Expression does not Correlate with Survival of Gastric Cancer Patients. *Pathology and Oncology Research*, **2017**, 23, 615-619	2.6	5
20	PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer. *Cellular Physiology and Biochemistry*, **2017**, 42, 2267-2280	3.9	65
19	Peripheral Deletion of CD8 T Cells Requires p38 MAPK in Cross-Presenting Dendritic Cells. *Journal of Immunology*, **2017**, 199, 2713-2720	5.3	
18	High mRNA expression level of IL-6R was associated with better prognosis for patients with ovarian cancer: a pooled meta-analysis. *Scientific Reports*, **2017**, 7, 8769	4.9	5
17	Ginsenoside PPDʈ Antitumor Effect via Down-Regulation of mTOR Revealed by Super-Resolution Imaging. *Molecules*, **2017**, 22,	4.8	9
16	TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	122
15	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222	10.2	3838
14	Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy. *Journal of Molecular Medicine*, **2016**, 94, 535-43	5.5	66
13	PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor. *Clinical Cancer Research*, **2016**, 22, 1173-1184	12.9	121
12	IL-36γ Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses. *Cancer Cell*, **2015**, 28, 296-306	24.3	62

11	Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. *Journal of Immunology*, **2015**, 194, 438-45	5.3	141
10	Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. *Journal of Immunology*, **2014**, 193, 1525-30	5.3	111
9	An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma. *PLoS ONE*, **2014**, 9, e91551	3.7	135
8	Impeded Nedd4-1-mediated Ras degradation underlies Ras-driven tumorigenesis. *Cell Reports*, **2014**, 7, 871-82	10.6	43
7	Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy*, **2012**, 8, 445-544	10.2	2783
6	T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract. *Immunologic Research*, **2011**, 50, 269-75	4.3	54
5	An Essential Role of the RNA Editing Enzyme ADAR1 in T Cell Development.. *Blood*, **2009**, 114, 917-917	2.2	
4	IL-17 helps autoimmune th1 responses. *FASEB Journal*, **2008**, 22, 1073.24	0.9	
3	Gadd45 Is Important for CD8+T Cell Mediated Tumor Surveillance. *FASEB Journal*, **2008**, 22, 1078.10	0.9	
2	Autophagy induction and autophagic cell death in effector T cells. *Autophagy*, **2007**, 3, 158-9	10.2	16
1	The molecular mechanisms that control function and death of effector CD4+ T cells. *Immunologic Research*, **2006**, 36, 275-82	4.3	23